An Australian veteran-owned pharmaceutical company has forged new supplier
partnerships to better support prescribing clinicians who treat veterans.
Provocatus, which provides veteran healthcare through its Veteran Access Scheme™
(VAS) and is licensed to supply medicinal cannabis in accordance with Australian
legislation, has partnered with ANTG, SatiVite and Novachem to expand its medicines
portfolio.
Managing Director Luke Gartner said the company’s expanded medicines offering is
part of Provocatus’ broader strategy of working closely with independent primary
healthcare providers managing holistic health needs.
“The Provocatus VAS program is designed to support veterans’ genuine health
requirements through the pillars of medications, appliances, clinical wellness and
education,” Gartner said.
“These new collaborations will boost our medications pillar and help to ensure
consistency, availability and alignment with prescribing practices, especially for
patients who require specific medicinal formats.
“Our strengthened range also provides prescribers comprehensive product options
for veterans without being aligned to a single supplier,” he said.
ANTG CEO Matthew Cantelo said the collaboration highlights a shared commitment
to responsible healthcare, patient safety and evidence-based prescribing.
“With ANTG’s deep roots in clinical research and our growing pipeline of clinical
trials, these products reflect the values that drive our business: science-led
innovation, robust evidence generation, and a dedication to patient wellbeing,”
Cantelo said.
“We also acknowledge the important role of Dr Michael Mumford and Provocatus in
ensuring veterans and prescribers receive the right education, support and
advocacy,” he said.
Mike Cleary, Founding Director at SatiVite, said his company is proud to work
alongside Provocatus in their dedication to improving the lives of veterans and their
families.
“Through this partnership, we’re helping make quality medicines more accessible for
those living with chronic conditions.”
Novachem Medical Products Manager, Andrew Heath, said the SyqeAir inhaler
included in the VAS represents a significant step forward in administering medicines.
“Our commitment to the Veteran Access Scheme is about more than just access, it’s
about dignity and outcomes,” Heath said.
“With SyqeAir, veterans are supported with a product that delivers both precision and
reliability.”
